2021
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgeryResectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity
Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Annals Of Surgical Oncology 2021, 28: 4953-4959. PMID: 33728541, DOI: 10.1245/s10434-021-09757-7.Peer-Reviewed Original ResearchMeSH KeywordsHumansNeoplasm Recurrence, LocalRisk AssessmentRisk FactorsSolitary Fibrous TumorsThoracic CavityConceptsSingle-institution reviewInstitution reviewFibrous tumorThoracic cavityLong-term survival dataGiant solitary fibrous tumorBackgroundSolitary fibrous tumorsKaplan-Meier analysisPredictors of recurrenceRare mesenchymal tumorLong-term outcomesRisk of recurrenceMajority of tumorsSolitary fibrous tumorLong-term survivalSFT recurrencePathologic characteristicsRisk stratificationTumor sizeMesenchymal tumorsRisk factorsTumor necrosisVisceral pleuraClinical informationRecurrence
2019
Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass
Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass. Journal Of Cardiothoracic Surgery 2019, 14: 158. PMID: 31488186, PMCID: PMC6728940, DOI: 10.1186/s13019-019-0980-1.Peer-Reviewed Original ResearchConceptsLeft internal mammary arteryDissection bedEstrogen receptorBreast cancerChest radiationHormonal therapyBypass surgeryRecurrent cancerNon-ST elevation myocardial infarctionCoronary artery bypass surgeryRecurrent metastatic breast cancerThree-vessel coronary artery bypassTumor cellsBreast intraductal carcinomaPrior chest radiationCoronary artery bypassArtery bypass surgeryInternal mammary arteryRecurrent breast cancerSaphenous vein graftsElevation myocardial infarctionMetastatic breast cancerHistory of cancerAreas of necrosisDense fibrous tissue
2016
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity
Woodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinomaChemoradiotherapy, AdjuvantEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoadjuvant TherapyNeoplasm Recurrence, LocalNeuroendocrine TumorsPostoperative ComplicationsProspective StudiesSurvival AnalysisThoracotomyTreatment OutcomeConceptsNeoadjuvant chemoradiationEsophagectomy approachesLong-term overall survival rateInvasive Ivor Lewis esophagectomyLow perioperative morbidityPostoperative complication rateClear survival benefitFive-year survivalIvor Lewis esophagectomyMajority of patientsOverall survival rateEsophageal cancer patientsInvasive esophagectomy (MIE) approachPatients 58Hospital stayNeoadjuvant treatmentPerioperative complicationsPerioperative morbidityPostoperative complicationsProspective databaseClinical characteristicsOverall survivalSurvival benefitComplication rateMajor complications
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes